Return to search

Novel Therapy against Malaria Resistance using Meta-analysis

Malaria causes severe illness and death in some cases if not treated on time. The most vulnerable people are children and pregnant women in areas where it is rampant. The causative agent of the most severe malaria is Plasmodium falciparum this parasite is transmitted by the female anopheles mosquito when infected with Plasmodium parasites. Southeast Asia and sub Saharan Africa have the highest malaria death rate. Meta-analysis is one of the statistical tools used for estimating the mean and variance of underlying effects of a population under study from a collection of data from empirical studies addressing same research question. Meta-analysis has become an increasing valuable tool in research. This study describes the meta-analysis of novel antimalarial drugs. It involved selection of eligible articles based on certain inclusion criteria, calculating effect sizes, conducting the actual analysis using a popular software such as IBM SPSS and thus, estimating the effects of publication bias. This study identified three novel therapies used to treat Artemisinin Combination Therapy (ACT) resistant malaria. The resistance against ACT is developed in malaria due to mutation in K13 gene. It is evident that these different novel therapies in combination with ACT treatment can be used to treat resistant malaria and reduce the mortality rate.

Identiferoai:union.ndltd.org:UPSALLA1/oai:DiVA.org:his-22042
Date January 2022
CreatorsOguntuyi, Adesola
PublisherHögskolan i Skövde, Institutionen för biovetenskap
Source SetsDiVA Archive at Upsalla University
LanguageEnglish
Detected LanguageEnglish
TypeStudent thesis, info:eu-repo/semantics/bachelorThesis, text
Formatapplication/pdf
Rightsinfo:eu-repo/semantics/openAccess

Page generated in 0.0016 seconds